A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
about
Targeting the Checkpoint to Kill Cancer CellsCancer's Achilles' Heel: Apoptosis and Necroptosis to the RescueDrugging the addict: non-oncogene addiction as a target for cancer therapyDetection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens.A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens.Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.DNA replication stress and cancer: cause or cure?Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.Looking beyond the cancer cell for effective drug combinations.The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies.Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer.Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.TBX19 is overexpressed in colorectal cancer and associated with lymph node metastasis.Inhibition of MK2 suppresses IL-1β, IL-6, and TNF-α-dependent colorectal cancer growth.Directing the use of DDR kinase inhibitors in cancer treatment.A Braf kinase-inactive mutant induces lung adenocarcinoma.Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.Upregulated solute carrier family 37 member 1 in colorectal cancer is associated with poor patient outcome and metastasis.HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130.RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors.CMPD1 inhibited human gastric cancer cell proliferation by inducing apoptosis and G2/M cell cycle arrest.Modulating ADME Properties by Fluorination: MK2 Inhibitors with Improved Oral Exposure.Anticancer drugs: A one-two punch for KRAS-driven cancer.
P2860
Q26795781-227B4786-8BFD-4902-92FA-53BE23C68ED3Q28066868-2111560D-6534-422B-8C53-EE0003E655BBQ28079559-2CD7D668-3097-4F99-80F5-B60777B229D2Q33798340-78D16C51-1DF1-42FA-8A18-66110938D1ECQ36283942-E03C1E32-074C-4E11-BF59-A13565187BF3Q36783008-928A74C1-1D76-44E0-AE07-B3C38525E1E6Q37634102-B2DE68EF-A7D2-4B74-A902-666CF11D0C7DQ38652528-85FC02E3-3E35-4489-9D66-D7D09F3C9BB3Q38708974-D4412A29-683F-444B-B388-5120B4084594Q38728970-30F874B2-067A-498E-9707-4D5E12D3143AQ38756275-C9F81F16-0A81-4C78-9CCF-8CAB7288DEF4Q38831146-12375BE4-AAF8-46C1-991E-3BBF565EFFD6Q38973740-22113A2A-1536-4CB5-96ED-68A7EE756E63Q39204274-4463F01C-E3A5-47BC-8948-59E9A32923D4Q42366556-979D69E2-F4C2-4A99-8BE8-D1E2307CE556Q47120183-15FF9037-966D-4ECF-B81D-324BC5F244B2Q47336772-0862021F-2061-42EB-8109-C8CDD5F9119EQ47339278-FAFCEDE8-8902-454A-B789-948277D56B82Q47687840-1A94EF9B-10A8-460B-9BFA-2AFD07643529Q47982952-150545EA-2C6D-4279-BFC7-E92F87D084E5Q48611990-A6EB0779-B9ED-4164-BCEF-EAA4B4CA3075Q49486006-F8C95AAA-C33B-407F-A9BA-1CE195305B71Q50317222-32E300FF-774D-47D3-9EFC-4A80E9C6212BQ52388109-12E9B739-F76B-410B-A29A-17A2E484C61EQ52585066-164FE0A5-5637-4D4F-9B3B-EC61CE942D54Q54115365-4EB496B3-913F-4DD4-A3FD-0C2B3166D86FQ54252850-C8A49E46-D55A-4223-A593-279CD99F30B9
P2860
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
@en
type
label
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
@en
prefLabel
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
@en
P2093
P50
P1433
P1476
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
@en
P2093
Alessandro Torgovnick
Alexander Strong
Allan Bradley
André Richters
Anna Schmitt
Bastian Kalb
Cornelia Mauch
Dieter Saur
Elisa M Noll
Felix Dietlein
P304
P356
10.1016/J.CELL.2015.05.053
P407
P50
P577
2015-07-01T00:00:00Z